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Introduction
Tuberculosis (TB) remains a very important infectious
disease in Hong Kong. In 1996, there were 6501 notifi-
cations of TB and 310 deaths, which corresponded to
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This consensus statement is prepared primarily as a concise reference for tuberculosis chemotherapy in Hong
Kong. Treatment should be tailored to patients individually, expert advice should be sought when necessary,
and ‘directly observed treatment’ should be used where possible. A 6-month regimen is recommended as the
initial treatment of uncomplicated pulmonary tuberculosis and a 9-month regimen is recommended for
retreatment. Patients with disease that is resistant to isoniazid or rifampicin may require modified regimens.
Multidrug-resistant tuberculosis should be managed in specialised centres, using multiple drugs as guided by
in vitro susceptibility tests. Recommended regimens to treat extrapulmonary tuberculosis are based on limited
current evidence, although shorter regimens may be acceptable when better evidence emerges. A longer
duration of treatment is required for diabetic, immuno-compromised, or silicotic patients. During pregnancy,
streptomycin should be avoided; the safety profiles of second-line drugs have not yet been ascertained.
Hepatotoxic drugs should be used with caution in patients with liver dysfunction, and extra caution and
dosage reductions are required if streptomycin and ethambutol are used in patients with renal impairment.
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crude notification and death rates of 103 per 100 000
and 5 per 100 000, respectively. As TB can affect organ
systems other than the lungs, doctors practising in
different fields may sometimes encounter patients with
this disease. The Tuberculosis Control Coordinating
Committee of the Hong Kong Department of Health
and the Tuberculosis Subcommittee of the Coordina-
ting Committee in Internal Medicine of the Hospital
Authority, Hong Kong, have jointly prepared the
following consensus statement, which primarily serves
as a reference and which is not meant to be exhaustive.
Indeed, the multitude of possible situations involving
TB1-9 preclude in-depth discussion of each in this
concise statement. The various clinical situations are
broadly classified into suitable categories. In each
category, recommendations on the treatment regimens
are made. However, because solid scientific data in a
number of areas are still lacking, on-going evaluation and
updating of such information will be required.
It is desirable for TB patients to be managed by or
in consultation with doctors experienced in this field.
Proper pretreatment assessment and careful monitoring
MEDICAL PRACTICE
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during treatment are necessary. The treatment plan
should be tailored for each individual patient. Drug
compliance is crucial for treatment success and pre-
vention of drug resistance. As far as possible, all
antituberculous drugs should be administered using
‘directly observed treatment’ to ensure patient com-
pliance. Apart from giving antituberculous drugs,
adjunctive measures such as the use of short courses
of corticosteroids10 can be useful to treat TB peri-
carditis and the late stages of TB meningitis, as well
as certain cases of TB lymphadenitis, TB pleural
effusion, fulminant pulmonary TB, genitourinary TB,
and some other forms of TB. Public health measures
should also be taken. All cases of TB should be
notified to the Department of Health using notification
form DH1A(s)(Rev.96)—this is a statutory require-
ment. Proper completion of all items in the form is
necessary to provide comprehensive data on the
surveillance of the disease.
Section I: pulmonary tuberculosis
Category A: uncomplicated tuberculosis
Category A1: primary treatment (no treatment
within the previous 5 years)
Recommendation*
2HRZ+(E or S) / 4HR
Four drugs—isoniazid, rifampicin, pyrazinamide, and
either ethambutol or streptomycin—are recommended
for the 2-month initial phase of treatment, as the rate
of initial resistance to isoniazid is more than 4% in
Hong Kong. Two drugs—isoniazid and rifampicin—
are recommended for the 4-month continuation phase,
which makes a total treatment duration of 6 months.
The drugs may be given daily or intermittently (three
times per week) in both the initial and the continuation
phase. The recommended dosages are listed in the Table.
The existing service programme in the chest clinics is
intermittent throughout the 6 months and is suitable for
patients who are receiving ambulatory treatment from
the start of chemotherapy. This regimen can also be
considered for those in-patients who have uncomplicated
TB and are soon to be discharged to chest clinics for
the continuation of ambulatory chemotherapy. The
efficacy is under continuous evaluation.
For patients with extensive disease, the 2-month initial
phase may be extended to 3 or 4 months, depending on
clinical, bacteriological, and radiological responses, while
the total duration of treatment may remain at 6 months.
If there is suspicion of drug-resistant TB (eg contacts of
patients with drug-resistant TB), the initial phase of
treatment may be similarly extended, pending the drug
sensitivity (ST) results.
Category A2: retreatment (for those who have
received treatment within the previous 5 years)
Recommendation
3(4)HRZES / 6(5)HR±E
Five drugs—isoniazid, rifampicin, pyrazinamide,
ethambutol, and streptomycin—are recommended for
* Notations used for TB treatment regimens in this consensus statement:
Drugs: E, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin; Z,
pyrazinamide
Duration: this is shown by the figures (in months) in front of the drug
combinations; the slash ‘/’ is used to separate different phases of treatment
Frequency: this is shown by the subscripts attached to the individual
drugs (ie subscript ‘3’ indicates thrice weekly; subscripts ‘5’, ‘6’, or ‘7’
indicate 5, 6, or 7 times weekly, respectively); absence of subscript
indicates either thrice weekly or daily—the commonly used convention
where the absence of a subscript indicates only daily frequency is not
used in this statement
Table. Dosages for first-line antituberculous drugs
Daily dosage Intermittent dosage (thrice weekly)
Adults and children Adults Adults and children Adults
(mg/kg) (mg/kg)
Weight (kg) Dose Weight (kg) Dose
Isoniazid (H) 5 – 300 mg 15 – –
Rifampicin (R) 10 <50 450 mg 15 – 600 mg
≥50 600 mg
Pyrazinamide (Z) 25-35 <50 1.5 g 50 <50 2.0 g
≥50 2.0 g ≥50 2.5 g
Ethambutol (E) 25 for 2 months – – 30 – –
then 15*
Streptomycin (S) 15-20 <50 500-750 mg† 15-20 <50 750 mg
≥50 750 mg† ≥50 1 g†
* 15 mg/kg for the entire treatment duration acceptable if patient is aged >70 years†
 If patient is aged >70 years, acceptable dosages are 500 mg daily and 750 mg thrice weekly
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the initial 3 to 4 months, depending on the timing of
the availability of ST results, the smear results, extent
of disease, and probability of drug-resistance. Isoniazid
and rifampicin (also with ethambutol if the disease
is extensive or the ST pattern is unknown) are recom-
mended for the continuation phase; the total treatment
duration is 9 months. If the ST results that are available
subsequently are unfavourable, the above regimen may
need to be modified (see Category B).
Category B: drug-resistant tuberculosis
There are no documented regimens for the treatment
of drug-resistant TB.11,12 It is important to avoid the
‘addition phenomenon’—namely, adding a single drug
to a failing regimen. Otherwise, acquired resistance
to the newly added drug may develop. Instead, add at
least two, three, or more drugs to which the organisms
are known to be susceptible, or which have not already
been taken by the patient. To assist in the management
of drug-resistant TB, the following regimens are
suggested for reference.
Category B1: resistance to isoniazid alone
Recommendations
(1) If the ST pattern is known before starting treatment:
2R7Z7E7S6  / 10R7Z7E7
(2) If ST results are reported during primary treatment
(as in Category A1):
(a) During primary treatment, the ST results
may become available during the continuation
phase when using the drug combination of
isoniazid with rifampicin. If resistance to
isoniazid is noted, the treatment regimen
should be changed to the daily administration
of rifampicin, pyrazinamide, and ethambutol
as follows:
2HRZ+(E or S) / (1-2)†HR / (9-8)†R7Z7E7
(b) For patients with:
(i) limited parenchymal involvement (total
area <15 cm2 on chest radiogram) without
cavitary disease; and
(ii) no pleural effusion; and
(iii) no histology showing positive acid-fast
bacilli:
If the response (clinical, radiological, and/or
bacteriological) to initial treatment is favourable,
the original 6-month regimen for uncomplicated
TB can be followed even when isoniazid
resistance is noted. After completion of treatment,
the patient should be observed for possible
relapse, the chance of which should be small. If
relapse occurs, review with the updated ST
pattern to guide the retreatment.
Apart from these regimens, clinical trials have
also shown that other regimens, such as 6HRZ+
(E or S) are useful in isoniazid-resistant disease.
Regimens such as 2HRZS / 4H3R3 and 2H3R3Z3S3 /
2H3R3S3 / 2H3R3, are also reasonable regimens and
have a relapse rate of less than 10%.
(3) If ST results are reported during retreatment, the
following regimen is recommended:
(3-4)†HRZES / (9-8)†R7Z7E7
Category B2: resistance to rifampicin alone
Recommendations
(1) If the ST pattern is known before starting treatment,
the following regimen can be given for a total
duration of 18 months, or 12 months after negative
culture:
(3-4)H7Z7E7S6  / H7Z7E7
(2) If ST results are reported during primary treatment,
the following can be given for a total duration of
18 months, or 12 months after negative culture:
2HRZ+(E or S) / (1-2)†HR / H7Z7E7
However, if before changing to a combination of
isoniazid, pyrazinamide, and ethambutol, an
acquired resistance to isoniazid is also suspected
or the treatment response is unsatisfactory (eg if
the sputum remains positive for acid-fast bacilli),
isoniazid, pyrazinamide, and ethambutol with
streptomycin (or other drugs) can be given in the
third phase, until the new ST results are available.
(3) If the ST results are reported during retreatment,
the following can be given for a total duration of
18 months, or 12 months after negative culture:
(3-4)†HRZES / H7Z7E7
Category C: multidrug-resistant tuberculosis
For the treatment of multidrug-resistant TB (MDR-
TB)—that is, TB that is resistant to at least isoniazid† Depending on the timing of availability of ST results
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and rifampicin, a combination of drugs to which the
organism is, or is likely to be, sensitive should be
used, namely, a regimen that comprises five or six
drugs for the initial 6 months and then three or four
drugs subsequently. Apart from the first-line anti-TB
drugs, other drugs available include the quinolones
(eg ofloxacin, levofloxacin, ciprofloxacin), amino-
glycosides (kanamycin, amikacin), prothionamide/
ethionamide, cycloserine, para-aminosalicylic acid,
and clofazimine.
The adequate duration of therapy for MDR-TB
has not been clearly identified. Some authorities recom-
mend a total duration of at least 18 to 24 months, or
24 months after negative culture. However, local
experience suggests that, with multiple drug treat-
ment and the inclusion of quinolones to which the
bacilli are still susceptible, the total duration may be
shortened to 12 to 18 months. The longer duration
may be required for patients with diabetes mellitus,
silicosis, slow sputum conversion, or extensive disease.
Treatment should be conducted in specialised
centres. It is essential to monitor the clinical, radio-
logical, and bacteriological progress, and to adjust
the treatment regimen or duration accordingly. Caution
is to be exercised in the use of second-line drugs, as
they are often associated with significant side effects.
Section II: extrapulmonary tuberculosis
As there have been few large-scale studies on the
treatment of extrapulmonary TB, consensus is often
lacking, especially in relation to the duration of treat-
ment. The following regimens are recommended for
reference to assist in the management of extra-
pulmonary TB. These recommendations are based on
limited current evidence and local experience, and may
have to be modified as better evidence for shorter
regimens emerge or as experience accumulates.3,5,6,8,13
Adjunctive corticosteroid therapy can be useful
in tuberculous pericarditis, tuberculous meningitis,
tuberculous lymphadenitis, tuberculous pleural
effusion, fulminant pulmonary TB, and genitourinary
TB.10
Category A: tuberculous meningitis (including
central nervous system tuberculoma)
Recommendation
3HRZE / 9HRZ
Streptomycin may also be added for the initial 2
months. Depending on computed tomography find-
ings and treatment response, some authorities may
extend the total duration of treatment up to 18 to 24
months for central nervous system tuberculoma.
Prolonged treatment may also be considered for
those who presented at a late stage (eg stage III) of
TB meningitis.13
Category B: miliary tuberculosis
Recommendation
3HRZ+(E or S) / 9HR
Category C: tuberculosis of bone and joint
Recommendation
2HRZE / 10HR
The total duration of treatment may be reduced to
6 or 9 months in the case of TB of the spine or in other
cases with mild disease.
Category D: tuberculous lymphadenitis
Recommendations
(1) For peripheral cervical disease where there are only
solitary/few affected lymph nodes in the upper
cervical chain or posterior triangle and the chest
X-ray is clear, the same treatment as stipulated in
Section I, Category A1 should be given for a total
duration of 6 months.
(2) Other situations are treated using the same regi-
men as in Section I, Category A1, but with the
continuation phase extended such that the total
duration of treatment is 9 months. One such
situation is peripheral cervical lymphadenopathy
with the same setting as (1) above but involving
many, enlarged lymph nodes, or supraclavicular
lymph nodes (with or without the chest X-ray
showing active TB). Another such situation is
mediastinal lymphadenopathy as detected by
computed tomography or plain X-rays, and
confirmed histologically.
It has to be noted that the clinical response of
TB of the lymph nodes during treatment may be quite
unpredictable, sometimes with paradoxical increases
in size probably due to immunological reactions.
Residual nodes may still be palpable after completing
the full course of treatment.
Category E: tuberculous pericarditis, tuberculous
peritonitis, and genitourinary tuberculosis
The recommendation is the same as in Section I,
Category A1, but the continuation phase is extended
such that the total duration of treatment becomes 9
months. For some cases that involve mild genitourinary
disease, 6 months of treatment may be adequate.
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Section III: pulmonary tuberculosis associated
with medical diseases or special settings
Category A: diabetes mellitus
The recommendation is the same as in Section I,
Category A1, but the continuation phase is extended
such that the total duration of treatment becomes 9
months.
Category B: immunocompromised patients
The recommendation is the same as in Section I,
Category A1, but the continuation phase is extended
such that the total duration of treatment becomes 9
months. For patients infected with the human immuno-
deficiency virus, the total duration of treatment should
be at least 9 months, or for 6 months after negative
culture.6,14 For retreatment and drug-resistant cases, the
treatment regimens are essentially similar to those for
the seronegative patients except that a longer duration
of treatment is required. Universal precaution and
infection control measures should be strictly observed
if drugs are to be given by injection.
Category C: pregnancy
Basically, rifampicin, isoniazid, ethambutol, and
pyrazinamide can still be used, although the manu-
facturers of rifampicin advise caution during pregnancy.
Pyridoxine is sometimes recommended for pregnant
women receiving isoniazid. Streptomycin should be
avoided because of ototoxicity to the foetus. The safety
profiles of the second-line drugs and ofloxacin have not
been ascertained and thus these drugs should also be
avoided. The taking of antituberculous drugs is itself not
a contra-indication to breast feeding.
Category D: children
The treatment regimens are essentially similar to those
for adults, except that ethambutol should be avoided in
children until they are at least 6 years old and capable
of reporting symptomatic visual changes accurately.
The drug dosages need to be calculated according to
the body weight and may have to be adjusted, especially
during the period of adolescent growth spurt.
Category E: silico-tuberculosis
A longer duration of treatment is required for patients
with silico-tuberculosis.15,16 The recommendations are
as follows:
(1) Initial treatment
2HRZ+(E or S) / 7HR or 8HRZ+(E or S)
(2) If there is a history of previous treatment
3HRZES / 6HR±E or 3HRZES / 5HRZ+(E or S)
If streptomycin is to be given for a prolonged period,
it is preferably given intermittently.
Category F: liver dysfunction
Transient bilirubin and alanine transaminase levels
changes are relatively common and do not signify
true hepatotoxicity. Drug-induced hepatitis, however,
necessitates withholding of all drugs.
When the tuberculous disease is mild or has already
improved markedly, wait until the results of the liver
function tests return to normal before retrial of con-
ventional antituberculous drugs. Whenever possible,
isoniazid and rifampicin should be included in the
regimen, so that treatment duration will not be unduly
long.
During extensive disease and pending full recovery
of liver function, ofloxacin can be used together with
streptomycin and ethambutol as an interim regimen.
This has been found to be successful for the majority
of such patients. Incorporation of ofloxacin as a com-
ponent of a definitive regimen should only be considered
when the patient cannot tolerate rifampicin and isoniazid
given concomitantly. The optimal dosage of ofloxacin is
unknown. Currently, experience shows that 400 to 600
mg once daily can be tolerated by the majority of patients.
The exact dosage to be given depends on age, body
weight, renal function, extent of disease, and number of
accompanying drugs. The optimal duration of ofloxacin
together with either isoniazid or rifampicin and etham-
butol as a definitive therapeutic regimen is unknown but
should be at least 1 year.
Category G: renal impairment
The development of drug-induced renal impairment is
an indication for withdrawal of the drug such as
streptomycin or rifampicin. If there is pre-existing renal
impairment, rifampicin, isoniazid, and pyrazinamide
can be given in the normal dosages. However, in severe
renal failure, it is recommended that isoniazid should
be given at 200 mg once daily with pyridoxine to avoid
peripheral neuropathy.
Streptomycin and ethambutol are the two main
drugs that are dependent on the renal route for
clearance. Extra caution should be exercised if these
drugs are to be used for patients with renal impairment.
Regular monitoring of renal function and adverse
reactions is mandatory. Appropriate dosage reduction
should be made.17 The guidelines in the literature
are not unequivocal. In fact, certain nephrologists have
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culosis and tuberculosis infection in adults and children.
American Thoracic Society and The Centers for Disease
Control and Prevention. Am J Respir Crit Care Med 1994;
149:1359-74.
9. Chan SL, Wong PC, Tam CM. 4-, 5- and 6-month regimens
containing isoniazid, rifampicin, pyrazinamide and strep-
tomycin for treatment of pulmonary tuberculosis under
program conditions in Hong Kong. Tuber Lung Dis 1994;
75:245-50.
10. Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis:
risks and use as adjunct therapy. Tuber Lung Dis 1993;74:
6-11.
11. Mitchison DA, Nunn AJ. Influence of initial drug resistance
on the response to short-course chemotherapy of pulmonary
tuberculosis. Am Rev Respir Dis 1986;133:423-30.
12. Davidson PT. Drug resistance and the selection of therapy for
tuberculosis. Am Rev Respir Dis 1987;136:255-7.
13. Humphries M. The management of tuberculous meningitis
[editorial]. Thorax 1992;47:577-81.
14. Scientific Committee of the Advisory Council on AIDS, Hong
Kong. Prevention and management of tuberculosis in HIV
infected patients in Hong Kong—an information paper. April
1995. Hong Kong: Scientific Committee of the Advisory
Council on AIDS, 1995.
15. Lin TP, Suo J, Lee CN, Lee JJ, Yang SP. Short-course chemo-
therapy of pulmonary tuberculosis in pneumoconiotic patients.
Am Rev Respir Dis 1987;136:808-10.
16. Hong Kong Chest Service/Tuberculosis Research Centre,
Madras/British Medical Research Council. A controlled clinical
comparison of 6 and 8 months of antituberculosis chemo-
therapy in the treatment of patients with silicotuberculosis in
Hong Kong. Am Rev Respir Dis 1991;143:262-7.
17. McEvoy CK, editor. American Hospital Formulary Service,
1996—drug information. New York: Authority of the Board
of Directors of the American Society of Health System
Pharmacists, 1996:405-6.
advised against the use of streptomycin for patients
who have significant renal impairment. Adjustment of
dosages would be required according to the degree of
renal impairment. This is an extremely difficult area
and the setting will be rendered more complicated by
dialysis. A nephrologist should be consulted whenever
doubt exists.
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